Hanren Dai

5.2k total citations · 1 hit paper
51 papers, 3.9k citations indexed

About

Hanren Dai is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Hanren Dai has authored 51 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 28 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Hanren Dai's work include CAR-T cell therapy research (32 papers), Immune Cell Function and Interaction (20 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Hanren Dai is often cited by papers focused on CAR-T cell therapy research (32 papers), Immune Cell Function and Interaction (20 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Hanren Dai collaborates with scholars based in China, United States and Russia. Hanren Dai's co-authors include Yao Wang, Weidong Han, Yelei Guo, Kaichao Feng, Qingming Yang, Zhiqiang Wu, Chuan Tong, Meixia Chen, Wenying Zhang and Yang Liu and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Hanren Dai

49 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models

2024 51 citations Hanren Dai, Xiaolei Li et al. profile →

Peers

Countries citing papers authored by Hanren Dai

Since Specialization

Citations

This map shows the geographic impact of Hanren Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanren Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanren Dai more than expected).

Fields of papers citing papers by Hanren Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanren Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanren Dai. The network helps show where Hanren Dai may publish in the future.

Co-authorship network of co-authors of Hanren Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Hanren Dai. A scholar is included among the top collaborators of Hanren Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanren Dai. Hanren Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigation of the role of GEM in systemic lupus erythematosus through multi-omics joint analysis 2025 ·Frontiers in Immunology ·(unknown), Xiao Zhang, (unknown), Hanxin Zhang, Xiaolei Li, Hanren Dai, Zongwen Shuai	0
2	The role of TREM2 in sepsis 2025 ·Journal of Clinical Investigation ·(unknown), Ting Sun, Hanren Dai	1
3	Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages 2024 ·Hepatology Communications ·(unknown), (unknown), Xu Zhang, Hanren Dai, Xiaolei Li, Hua Wang	5
4	GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of Macrophages to Acquire Anti-Inflammatory Properties 2023 ·Cellular and Molecular Gastroenterology and Hepatology ·Xiaolei Li, (unknown), (unknown), Xu Zhang, Wentao Xu, Hanren Dai, Hua Wang	32
5	Mesenchymal stromal/stem cells and their extracellular vesicles in liver diseases: insights on their immunomodulatory roles and clinical applications 2023 ·Cell & Bioscience ·(unknown), Cheng Zhu, Xu Zhang, Hanren Dai, Xiaolei Li, Hua Wang	17
6	Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer 2022 ·BMC Gastroenterology ·Cheng Zhu, Siya Wang, (unknown), Ying Dai, (unknown), Xiaolei Li, Yingying Du, Hanren Dai, (unknown), Shi Yin, Hua Wang	13
7	Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done? 2021 ·Cellular and Molecular Immunology ·Xiaolei Li, Hanren Dai, Xian Li, Ping Li, Wenbin Qian, Aibin Liang, Weidong Han	1
8	Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy 2021 ·OncoImmunology ·Xiaolei Li, Hanren Dai, Hua Wang	3
9	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming 2021 ·Nature Communications ·Yao Wang, Chuan Tong, Hanren Dai, Zhiqiang Wu, Han Xiao, Yelei Guo, Deyun Chen, Jianshu Wei, Dongdong Ti, Zongzhi Liu, Qian Mei, Xiang Li, Liang Dong, Jing Nie, (unknown), Weidong Han	160
10	Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial 2020 ·Cytotherapy ·Yang Liu, Yelei Guo, Zhiqiang Wu, Kaichao Feng, Chuan Tong, Yao Wang, Hanren Dai, Fengxia Shi, Qingming Yang, Weidong Han	125
11	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia 2020 ·Journal of Hematology & Oncology ·Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Han Xiao, Yang Liu, Wenying Zhang, Chunmeng Wang, (unknown), Meixia Chen, Qingming Yang, Yao Wang, Weidong Han	227
12	Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix 2019 ·British Journal of Cancer ·Wenlong Zhang, Ling Liu, Huifang Su, Qin Liu, Jie Shen, Hanren Dai, Wei Zheng, Yan Lü, Weijie Zhang, Yuncheng Bei, Pingping Shen	223
13	Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation 2019 ·Journal of Hematology & Oncology ·Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Han Xiao, Qingming Yang, Zhiqiang Wu, Weidong Han	48
14	Restoration of CD3+CD56+ cell level improves skin lesions in severe psoriasis: A pilot clinical study of adoptive immunotherapy for patients with psoriasis using autologous cytokine-induced killer cells 2018 ·Cytotherapy ·Hanren Dai, (unknown), Chuan Tong, Yelei Guo, Fengxia Shi, Yao Wang, Pingping Shen	5
15	Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers 2017 ·Clinical Cancer Research ·Yelei Guo, Kaichao Feng, Yang Liu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Hejin Jia, Weidong Han	196
16	Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma 2017 ·Journal of Hematology & Oncology ·Kaichao Feng, Yelei Guo, Yang Liu, Hanren Dai, Yao Wang, Haiyan Lv, Jianhua Huang, Qingming Yang, Weidong Han	202
17	Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial 2016 ·Clinical Cancer Research ·Chunmeng Wang, Zhiqiang Wu, Yao Wang, Yelei Guo, Hanren Dai, Xiaohui Wang, Xiang Li, (unknown), Wenying Zhang, Meixia Chen, Yan Zhang, Kaichao Feng, Yang Liu, Su‐Xia Li, Qingming Yang, Weidong Han	261
18	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer 2016 ·Science China Life Sciences ·Kaichao Feng, Yelei Guo, Hanren Dai, Yao Wang, Xiang Li, Hejin Jia, Weidong Han	228
19	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells 2014 ·Clinical Immunology ·Yao Wang, Wenying Zhang, Qingwang Han, Yang Liu, Hanren Dai, Yelei Guo, Jian Bo, Hui Fan, Yan Zhang, (unknown), Meixia Chen, Kaichao Feng, Quanshun Wang, Xiaobing Fu, Weidong Han	162
20	Inhibitory effect of magnesium isoglycyrrhizinate on proliferation of chronic myelogenous leukemia K562 cell line 2010 ·Hanren Dai	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact